Vanda Pharmaceuticals (VNDA): Director bought ~$13K

~$13K

Approx. value · 3,447 sh @ $3.82

103K

Holds after · shares reported

Traded

Nov 4, 2026

Filed

Nov 5, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 9, 20265% stakeMillennium Management LLC reported a passive stake (13G) of 7.0%
2. Oct 27, 20265% stakeBlackRock Portfolio Management LLC reported a passive stake (13G) of 5.9%
3. Oct 28, 2026Company filing · Form 8-K · ResultsReported its results
4. Nov 3, 2026Insider · First insider buy since Aug 2025Director purchased ~$2.8K of VNDA shares in the open market
5. Nov 4, 2026 · this disclosureInsiderDirector purchased ~$13K of VNDA shares in the open market

What came next

1. Nov 5, 2026InsiderDirector purchased ~$22K of VNDA shares in the open market
2. Nov 10, 20265% stakeSTATE STREET CORPORATION reported a passive stake (13G) of 5.0%
3. Nov 13, 20265% stakeAQR Capital Management, LLC reported a passive stake (13G) of 3.5%

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Vanda Pharmaceuticals

For Vanda Pharmaceuticals, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VNDA page.

Other recent filings by Charles Cliff Duncan, Director

• SEC Form 4 at Vanda Pharmaceuticals (VNDA)Nov 5, 2026
• SEC Form 4 at Vanda Pharmaceuticals (VNDA)Nov 5, 2026

The full history of Charles Cliff Duncan, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Vanda Pharmaceuticals

• SEC Schedule 13GNov 13, 2026
• SEC Form 4Nov 5, 2026
• SEC Form 4Nov 5, 2026
• SEC Form 4Aug 8, 2025
• SEC Form 4Jun 17, 2025
• SEC Form 4May 22, 2025

Everything OQRO holds on this company is on its VNDA page.